SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

NCT ID: NCT05846789

Last Updated: 2026-01-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 168 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-02
• Study Completion Date: 2026-12-31

Brief Summary

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

Detailed Description

Randomized phase II using a two-stage Bayesian optimal phase II two-arm design (BOP2). Patients are randomized 1:1 to either the monotherapy or combination arms. This requires 42 patients (21 per treatment arm) in stage I for each race-based cohort. If the no. of response in experimental - no. of response in control is no greater than -1, the trial is early stopped at stage I for futility. Otherwise, additional 42 patients for each race-based cohort will be enrolled and randomized to the study in stage II.

Conditions

Metastatic Breast Cancer; Triple Negative Breast Cancer; Estrogen-receptor-low Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Black Monotherapy

Group Type: ACTIVE_COMPARATOR

SOC Chemotherapy

Intervention Type: DRUG

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Black Combination treatment

Group Type: EXPERIMENTAL

SOC Chemotherapy

Intervention Type: DRUG

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Tocilizumab

Intervention Type: DRUG

Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks

Non-Black Monotherapy

Group Type: ACTIVE_COMPARATOR

SOC Chemotherapy

Intervention Type: DRUG

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Non-Black Combination treatment

Group Type: EXPERIMENTAL

SOC Chemotherapy

Intervention Type: DRUG

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Tocilizumab

Intervention Type: DRUG

Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks

Interventions

SOC Chemotherapy

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Intervention Type: DRUG

Tocilizumab

Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥ 18 years old at the time of informed consent

2. Ability to provide written informed consent and HIPAA authorization

3. Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-low (ER and PR ≤ 9% weak staining)

4. Received up to 2 prior therapies for metastatic disease

1. Prior (neo)adjuvant therapy will be considered one line of therapy for metastatic disease in patients who recur while on or within 12 months of completion of (neo)adjuvant therapy.

2. Participation in this protocol as either first, second and third-line therapy is allowed.

5. Planned standard of care chemotherapy based on NCCN guidelines.

1. Single agent therapy is preferred but use of combination regimens considered SOC by NCCN is allowed.

2. Chemotherapy delivered via a SOC antibody-drug conjugate is allowed but ADCs may not be used in combination with other agents.

6. Patients with tumors that are PD-L1+ (CPS > 10) must have had prior exposure to an immune checkpoint inhibitor in the metastatic setting.

1. Patients who received (neo)adjuvant IO therapy and progress while on or within 12 months of completion of (neo)adjuvant IO therapy may participate without additional IO treatment.

2. Patients with major contraindications to immune therapy, may participate without IO exposure regardless of PD-L1 status in the first line setting.

3. PD-L1 status is not required for patients in the second line setting.

7. Measurable disease based on RECIST 1.1 criteria.

8. Disease amenable to and consent for study-specific biopsy NOTE: If no disease amenable to biopsy is present at the time of second biopsy, subjects may continue participation in the study and further study specific biopsies will not be required.

9. ECOG PS 0 or 1

10. Patients with treated, asymptomatic CNS disease may participate if the patient is > 4 weeks from completion of CNS therapy (radiation and/or surgery), is clinically stable at the time of study entry, and is receiving stable or decreasing dose of corticosteroids. Brain MRI or head CT is required at screening for patients with known brain metastases.

11. Adequate organ function as indicated by:

1. Total bilirubin < ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 x ULN

3. Creatinine clearance of > 50 mL/min using the Cockcroft-Gault formula

4. Absolute neutrophil count (ANC) > 1.2 K/mm3

5. Platelets > 75 K/ mm3

6. Hgb > 9.0 g/dL

12. Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:

1. Has undergone a hysterectomy or bilateral oophorectomy; or

2. Has been naturally amenorrheic for at least 24 consecutive months.

13. Women of childbearing potential and men must agree to use effective contraception throughout the study and for 6 months after the last study treatment.

NOTE: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).

Exclusion Criteria

1. Prior treatment with or known contraindication to treatment with tocilizumab or other IL-6/IL-6R targeted agent

2. Active infection requiring parenteral antibiotics

3. Concurrent use of methotrexate or systemic corticosteroids other than stable or decreasing doses for management of CNS involvement

4. Active or symptomatic CNS disease

5. Patients with HER2+ disease Note: HER2 will be considered positive if scored 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of > 2.0 or > 6 total HER2 gene copies per cell.

6. Patients with active malignancy other than breast cancer. Patients with prior malignancies without recurrence after standard treatment will not be excluded

7. Radiation therapy within 2 weeks of registration

8. Hormone therapy within 2 weeks of registration

9. Planned treatment with Olaparib or other PARP inhibitor.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Breast Cancer Research Foundation

OTHER

Sponsor Role: collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

Sponsor Role: collaborator

Kathy Miller

OTHER

Sponsor Role: lead

Responsible Party

Kathy Miller

Ballvé-Lantero Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Kathy Miller, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Emory University

Atlanta, Georgia, United States

Site Status: RECRUITING

IU Health Joe and Shelly Schwarz Cancer Center

Carmel, Indiana, United States

Site Status: RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States

Site Status: RECRUITING

Sidney and Lois Eskenazi Hospital

Indianapolis, Indiana, United States

Site Status: RECRUITING

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Site Status: RECRUITING

Duke University

Durham, North Carolina, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Xin Bryan, RN

Role: CONTACT

zhongx@iupui.edu

317-274-5495

Facility Contacts

Carlos Aguilera, BA

Role: primary

winshipcto@emory.edu

404-778-1868

Xin Bryan, RN

Role: primary

zhongx@iupui.edu

317-274-5495

Lindsay Moshides, MS

Role: primary

Lindsay.Moshides@RoswellPark.org

716-854-1300 ext. 6328

Samantha Womack, BA

Role: primary

sam.womack@duke.edu

919-660-1278

Other Identifiers

CTO-IUSCCC-0817

Identifier Type: -

Identifier Source: org_study_id